The longevity community's most-studied molecule. 60+ years of safety data, AMPK activator, central to the landmark TAME (Targeting Aging with Metformin) trial. Taken by Peter Attia, David Sinclair, and every serious longevity researcher.
Metformin activates AMPK—the master cellular energy sensor—mimicking caloric restriction at the molecular level. This shifts cells from anabolic growth mode to catabolic maintenance and repair. The mechanisms are well-characterized and supported by decades of research across species.
Metformin has the most robust evidence base of any longevity intervention in humans. The TAME trial, currently enrolling 3,000 participants, will be the first large-scale randomized controlled trial specifically testing longevity effects. Observational data suggests substantial benefits.
Book a consultation with a licensed physician to discuss whether metformin ER is appropriate for your longevity protocol.